Introduction
============

Use of extracorporeal life support (ECLS) in trauma casualties is limited by concerns regarding hemorrhage, particularly in the presence of traumatic brain injury (TBI). We report usage of ECMO/ interventional lung assist (iLA) as salvage therapy in 13 trauma patients. A high-flow technique without anticoagulation was used in cases with coagulopathy or severe TBI.

Methods
=======

Data were collected from all adult trauma cases referred to one center for ECMO/iLA treatment due to severe hypoxemic respiratory failure. Thirteen consecutives cases are reported. The type of assistance was chosen based on a flowchart. Type of study: therapeutic, level of evidence IV. We analyzed patient data, injury data, blood gases before connection, methods of assistance, coagulation study, complications, survival and neurological outcome.

Results
=======

Thirteen casualties had an average Injury Severity Score of 50.3 ± 10.5 (age 27.7 ± 8.6 years, 69.2% male) and were supported 9.9 ± 4.8 days on ECMO (*n*= 7) and 7.16 ± 5.9 days on iLA (*n*= 6). All suffered severe chest injuries, including one cardiac perforation. Most were coagulopathic prior to initiation of ECMO/iLA support. Among the seven patients with TBI, four had active intracranial hemorrhage. Only 30% of the patients received continuous anticoagulation during the first 24 hours of support without clotting of the system or diagnosis of a thromboembolic event. Complications directly related to support therapy were not lethal; these included hemorrhage from a cannulation site (*n*= 1), accidental removal of a cannula (*n*= 1) and pressure sores (*n*= 3). Deaths occurred due to septic (*n*= 3) and cardiogenic shock (*n*= 1). Survival rates were 57 and 83% on ECMO and iLA, respectively. Follow-up of survivors detected no neurological deterioration.

Conclusion
==========

ECMO/iLA therapy can be used as rescue therapy in adult trauma cases with severe hypoxemic respiratory failure, even in the presence of coagulopathy, bleeding and/or brain injury. The benefits of oxygenation and circulatory support must be weighed individually against the risk of hemorrhage. Further research should determine whether ECMO therapy also confers survival benefit.
